Clinical Trial Update: Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 clinical trial evaluating cemiplimab in combination with low-dose paclitaxel and carboplatin for recurrent or meta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Squamous Cell Carcinoma of Unknown Primary

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Cemiplimab (Libtayo) (cemiplimab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Marcelo Bonomi | Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING